Novartis ends eight-year cancer drug dispute for $182m

Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Big Pharma

Novartis asks court for access to rival’s documents over trade secrets claims

26 October 2023 Swiss multinational says competitor has been “uncooperative” in investigation into whether former Novartis employee took trade secrets |Novartis files complaint for discovery, asking for permission to issue subpoena.

Big Pharma

Why Novartis lost its treatment dispute with Teva

17 January 2023 The pharma company’s arguments focusing on ‘inventive step’ failed to convince a London court that the Israeli generic drug maker had infringed, explains Azadeh Vahdat of EIP.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Novartis ends eight-year cancer drug dispute for $182m

More on this story

Editor's picks

Editor's picks

More features